Xarelto Defendants: Third Time Lucky
Xarelto Defendants: Third Time Lucky
Introduction
The third straight win for Xarelto defendants in the Xarelto MDL No. 2592 bellwether trial, boosts the defendant's stand regarding the safety and efficacy of Xarelto. Bayer released a statement saying, ''that its FDA-approved label contains accurate, science-based information on the benefits and risks of this life-saving medicine.” This decision came in by the Mississippi federal jury in favor of the defendants: J&J's Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. The plaintiff alleged that the Prothrombin Time (PT) test which is used to assess a patient's risks for bleeding, was not informed and instructed to the doctors by the manufacturers. This was opposed by the defendant's say that the PT test was not scientifically reliable.
Comments
Latest News
NC to Get $150M to Boost Opioid Treatment, Recovery
Categories: Opioids
North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid…
SRI Gets FDA OK for High-Dose Naloxone Trial
Categories: Opioids
SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.
The approval was granted under an Investigational New Drug (IND)…
Spokane County to Get $5M in New Opioid Settlement
Categories: Opioids
Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.
The agreement addresses the company’s role in fueling…